Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Concomitant Bexsero and Menveo in Adolescents
NCT04318548Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal infection, sponsored by GSK. Started Aug 2020; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT04318548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04318548.